API | silmitasertib

silmitasertib Report issue

Small molecule Experimental

AACT ChEMBL MeSH PubChem

Active Ingredient History

NOW

Silmitasertib (INN), codenamed CX-4945, is a small-molecule inhibitor of protein kinase CK2, a constitutively active serine/threonine-specific protein kinase that is overexpressed in several types of tumors. ^Wikipedia

Chemistry

SMILES: O=C(O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc12
InChIKey: MUOKSQABCJCOPU-UHFFFAOYSA-N
Mol. Mass: 349.78
ALogP: 4.88 Partition coefficient
ChEMBL Molecule:
silmitasertib

More Chemistry

Pharmacology

Mechanism of Action:
- Casein kinase II subunit alpha (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

5-(3-chlorophenylamino)benzo(c)(2,6)naphthyridine-8-carboxylic acid | cx4945 | cx 4945 | cx-4945 | silmitasertib

Organizations (8)

Research & Development (8)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (10)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (10)

Breast Neoplasms (Phase 1)

Carcinoma, Basal Cell (Phase 1)

Castleman Disease (Phase 1)

Cholangiocarcinoma (Phase 1/Phase 2)

Coronavirus (Phase 2)

COVID-19 (Phase 2)

Inflammatory Breast Neoplasms (Phase 1)

Medulloblastoma (Phase 1/Phase 2)

Multiple Myeloma (Phase 1)

Neoplasms (Phase 1)

Overview

Highest Phase: Phase 2
# of Trials: 8
# of Trial Organizations: 8

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue